Article · 3 Jan 2024
Conference abstractPublished 21 Oct 2013
Key performance indicator implementation by regulatory affairs
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The process by which organizations align their global and local resources processes, tools, internal and external resources to strategic objectives and priorities is ?Performance Management?, which is supported by Key Performance Indicators (KPIs). Various dashboards, like Balance Scorecard (BSC) and Individual Objectives include the KPIs. The setting of meaningful Regulatory Affairs (RA) KPIs is one of most challenging of the pharmaceutical industry due to the difficulty to measure the quality of a submission in term of long-term value and to ensure that the chosen regulatory strategy would meet the long-term trend by the agencies. The pitfall of measuring short term success as the number of approvals or renewals which are not always linked to marketing goals demonstrate the necessity of multi-year KPIs with top-down and bottom-up approaches and alignment with R&D, marketing and global and local units. Tactical points, like manufacturing variations are part of them. The art of Performance Management by RA is to implement KPIs covering the six basic perspectives: Finance, R&D pipeline, marketing, internal business process, external compliance and learning. RA KPIs contribute heavily to the company success. Many RA KPIs are endorsed totally or partially by most of the company departments. One of the challenges of the KPI implementation is the related payout as bonus based one year period as the RA KPI results are measured over many years. Practical examples, included KPI sharing with external providers, illustrate the risks and benefits of classes of Regulatory Affairs KPIs which promote good behaviors and avoid possible misuses.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 14 Jul 2022
Clinical Pharmacy Key Performance Indicators (cpKPI) for Hospital Pharmacists in Nigeria
Research article · 28 Feb 2022
Implementation of Quality by Design Methodology in Development and Validation of a New Stability-Indicating, Reverse Phase High-Performance Liquid Chromatography Method for the Rapid Estimation of Piribedil in Piribedil Prolonged Release Tablets
Opinion · 4 Feb 2026
Regulatory Affairs Should Be Viewed as a Driver of Innovation Rather Than a Barrier to Drug Development
Short communication · 29 Nov 2025
Strategic Pharmaceutical Regulatory Affairs for Global Success
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 13 Feb 2026
Regulatory Scenario of Pharmaceuticals during COVID-19 Pandemic in India
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Philippe Berclaz”

